The Journal of pharmacy and pharmacology

The most recent articles from: August 2015

  • J. Pharm. Pharmacol. · Aug 2015

    Review

    Rivaroxaban for the treatment and prevention of thromboembolic disease.

    A number of direct oral anticoagulants are now available and offer alternative strategies for anticoagulation therapy. Rivaroxaban, a direct oral Factor Xa inhibitor, is approved for use across several thromboembolic indications. This article aims to provide an overview of the key pharmacological characteristics of rivaroxaban and the rationale and evidence for the use of different dose regimens across its licenced indications, and offer practical guidance to healthcare professionals on responsible use. References were sourced via PubMed searches using the search string (rivaroxaban AND (pharmacokinetics OR pharmacodynamics OR (clinical studies) OR (drug interaction)) NOT review NOT (children OR pediatrics OR paediatrics OR adolescent)). ⋯ Rivaroxaban may offer an anticoagulant option that could simplify and improve the management of patients with thromboembolic disorders.

    read more… mark as read…

Want more great medical articles?

Keep up to date with a free trial of metajournal, personalized for your practice.
1,694,794 articles already indexed!

We guarantee your privacy. Your email address will not be shared.